About | MyQuidel | Investor Relations | Reimbursement 1.800.874.1517

Search. CARFERS

MOLECULAR DIAGNOSTICS

**IMMUNOASSAYS** 

DHI CELL CULTURE & FLUORESCENT TESTS

RESEARCH

CUSTOMER SUPPORT



# MicroVue Complement C3a Plus EIA

For Research Use Only in the United States. Not for use in diagnostic

The MicroVue C3a Plus EIA measures the amount of C3a-desArg present in human plasma and serum.

C3a is generated during the activation of the complement system via the classical or alternative pathway. The anaphylatoxin C3a itself is very short lived and in serum is cleaved rapidly to the more stable C3a-desArg. Therefore, quantitation of C3a-desArg allows reliable conclusions about the level of complement activation in a test sample. For convenience, we refer to both forms as C3a. The MicroVue C3a Plus EIA measures concentrations of C3a in human plasma and sera. It uses a proprietary monoclonal antibody to a neo-epitope on C3a to capture C3a in the solid phase. The trapped C3a is subsequently detected by HRP-labeled antibodies to C3a antigens. This test provides a rapid, nonradioactive method for assessing C3a levels. It is designed for investigations into the role and or status of complement activation in numerous research and clinical settings. An EIA for the detection of C3a (C3a-desArg) in human serum and plasma.

### References

Sefton, M.V., et al. Using ELISA to evaluate complement activation by reference biomaterials, J Materials Science, 5:622-627, 1994.

Mold, C, Tamerius, J.D., et al. Complement activation during painful crisis in sickle cell anemia, Clinical Immunology and Immunopathology, 70:3,314-320, 1995.

Rinder, C, et al., Blockade of C5a and SC5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation, J. Clin. Invest., 96:3,1564-

Rollins, et al. Monoclonal Antibodies directed against human C5 and C8 block complement mediated damage of xenogenic cells and organs, Transplantation, 60:11, 1284-1292, 1995.

Sorace, J., et al., Role of atheroma liposomes and malondialdehyde modified low density lipoproteins in complement activation, Pathobiology, 64:73-78, 1996.

Shorey, et al. A macrophage invasion mechanism of mycobacteria, Science, 277:1091-93, 1997.

Yeh, G., et al. A soluble chimeric complement inhibitory protein that possesses both DAF and Factor I cofactor activities, J. Immuno., 158:2872-2881, 1997.








(6) HOW TO BUY (1) REQUEST INFO (2) REIMBURSEMENT

Home » Research » ELISA kits » MicroVue C3a Plus EIA\*



Features & Benefits **Product Specifications Ordering Information Product Documentation**  Complement Activation and **Biological Functions Video** 



Browse by Brand
MicroVue
BioPorto
Pathway
TECOmedical

Immutopics

HOW TO BUY

**EVALUATE A KIT** 

#### Molecular Diagnostic Assays Research How to Buy Cancer Research Products Bone Health Reagents Immunoassay Kits Reimbursement Complement Depleted Sera Inflammatory & Autoimmune Complement Proteins Metabolic Syndrome **DHI Cell Culture &** Osteoporosis (Bone&Health) Complement Reagents Fluorescent Antibody Tests About Quidel ELISA Kits (EIA) MicroVue Monoclonal Antibodies **TECOmedical** Polyclonal Antisera Locations & Directions **Customer Support** Contact Us Quidel News Careers

## Quidel Corporation Headquarters:

12544 High Bluff Drive, Suite 200, San Diego, CA 92130, USA 858.552.1100 Tel 858.453.4338 Fax Copyright © 2008-2019 Quidel Corporation. All rights reserved.

Website Terms and Conditions • Privacy Policy • Site Map

## LEGAL NOTICE

By accessing, browsing and/or using this website, you acknowledge that you have read, understood, and agree to be bound by Quidel's Website Terms and Conditions, Privacy Policy and to comply with all applicable laws and regulations. If you do not agree to these terms, do not use the website. Additionally, this website contains information on products that is targeted to many different audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for your accessing such information that may not comply with any legal process, regulation, registration or usage in the country of your origin.